

**Baxter International Inc.**  
**Key Product Line Sales**  
**Period Ending September 30, 2005**  
(unaudited)

(\$ in millions)	Q3 2005	Q3 2004	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2005	YTD 2004	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>								
Recombinants	\$392	\$341	15%	15%	\$1,133	\$953	19%	16%
Plasma Proteins <sup>1</sup>	242	254	(5%)	(6%)	767	759	1%	(2%)
Antibody Therapy	123	82	50%	50%	305	252	21%	19%
Transfusion Therapies	134	124	8%	6%	407	400	2%	(1%)
Other <sup>2</sup>	59	48	23%	23%	230	188	22%	19%
<b>Total BioScience</b>	<b>\$950</b>	<b>\$849</b>	<b>12%</b>	<b>11%</b>	<b>\$2,842</b>	<b>\$2,552</b>	<b>11%</b>	<b>9%</b>
<b>Medication Delivery</b>								
IV Therapies <sup>3</sup>	\$301	\$275	9%	7%	\$909	\$845	8%	4%
Drug Delivery	192	198	(3%)	(4%)	622	588	6%	5%
Infusion Systems	184	248	(26%)	(27%)	659	669	(1%)	(3%)
Anesthesia	259	248	4%	4%	772	749	3%	2%
Other <sup>4</sup>	21	17	24%	18%	56	67	(16%)	(19%)
<b>Total Medication Delivery <sup>5</sup></b>	<b>\$957</b>	<b>\$986</b>	<b>(3%)</b>	<b>(4%)</b>	<b>\$3,018</b>	<b>\$2,918</b>	<b>3%</b>	<b>1%</b>
<b>Renal</b>								
PD Therapy	\$381	\$361	6%	3%	\$1,140	\$1,063	7%	4%
HD Therapy	105	123	(15%)	(17%)	345	365	(5%)	(10%)
Other	5	1	400%	400%	13	10	30%	30%
<b>Total Renal</b>	<b>\$491</b>	<b>\$485</b>	<b>1%</b>	<b>(1%)</b>	<b>\$1,498</b>	<b>\$1,438</b>	<b>4%</b>	<b>-%</b>
<b>TOTAL BAXTER</b>	<b>\$2,398</b>	<b>\$2,320</b>	<b>3%</b>	<b>2%</b>	<b>\$7,358</b>	<b>\$6,908</b>	<b>7%</b>	<b>4%</b>

<sup>1</sup> Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

<sup>2</sup> Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

<sup>3</sup> Principally includes intravenous solutions and nutritional products.

<sup>4</sup> Principally includes other hospital-distributed products.

<sup>5</sup> Sales of oncology products, which were previously included in Other, are now reported in Drug Delivery, Infusion Systems or Anesthesia, depending on the product. All prior year sales data has been reclassified to reflect this change.